Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.

SNO Oral Presentation Details:
Title: AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis
Abstract Number: EXTH-02
Abstract Session: CNS Metastases
Presenter: Dan R. Laks, Ph.D., Scientist II, Voyager Therapeutics
Presentation Time: 4:15 p.m. ET

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company‚Äôs TRACERTM screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas.        LinkedIn        Twitter


Voyager Contacts

Scott Santiamo

Primary Logo

Back to news